FRI0142 Efficacy of the Initial Treatment with Certolizumab Pegol for Rheumatoid Arthritis: A Multicenter Study
Authors: Y. Hattori, A. Kaneko, D. Kida, Y. Kanayama, Y. Hirano, H. Kanda, T. Kojima, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> We evaluate the efficacy of the loading dosage with certolizumab pegol (CZP) for rheumatoid arthritis (RA). <h3>Methods</h3> We analyzed 34 patients with RA who underwent CZP treatment with the loading dosage of 400 mg every alternate week until 4 weeks and 137 patients with RA who underwent adalimumab (ADA) treatment with the standard regimen of 40 mg every alternate week in the multicenter study group (Tsurumai Biologics Communication Registry; TBCR) were enrolled in this study. All patients had not received previous biologic treatment (Table). We compared the efficacy of initial treatment for RA patients in CZP group and ADA group. <h3>Results</h3> In patients continuing at 4 weeks, the baseline methotrexate dose and DAS28-CRP had significance in CZP group and ADA group. However, the baseline CRP value had no significance in CZP group and ADA group (Table). Percentage of paints who achieved 20% rate of improvement of CRP level at 4 weeks in CZP group is significantly higher than in ADA group. Percentage of paints who achieved 50% rate of improvement of CRP level at 4 weeks in CZP group is higher than in ADA group. Percentage of paints who achieved 70% rate of improvement of CRP level at 4 weeks had no significance in CZP group and ADA group (Fig. 1). According to the EULAR response criteria using the DAS28, percentage of paints who achieved no response and moderate response at 4 weeks in CZP group is lower than in ADA group. Percentage of paints who achieved good response at 4 weeks in CZP group is significantly higher than in ADA group (Fig. 2). <h3>Conclusions</h3> In this study, the response of treatment in CZP group at 4 weeks is better than in ADA group, and there were few ineffectiveness cases in CZP group. We suggested that the loading dosage developed sure efficacy of the initial treatment with CZP for RA. <h3>Disclosure of Interest</h3> Y. Hattori Grant/research support from: Chugai Pharma Corporation, Pfizer, Abbvie, UCB, Bristol-Myers Squibb, Janssen Pharma, and Nichi-Iko Pharmaceutical Corporation., A. Kaneko Grant/research support from: Chugai Pharma Corporation, Pfizer, Abbvie, UCB, Bristol-Myers Squibb, Janssen Pharma, and Nichi-Iko Pharmaceutical Corporation., D. Kida Grant/research support from: Chugai Pharma Corporation, Pfizer, Abbvie, UCB, Bristol-Myers Squibb, Janssen Pharma, and Nichi-Iko Pharmaceutical Corporation., Y. Kanayama Speakers bureau: Astellas Pharma, Y. Hirano Speakers bureau: Abbvie, Mitsubishi Tanabe Pharma Corporation, Pfizer, Eisai Pharma Corporation, Chugai Pharma Corporation, and Bristol-Myers Squibb., H. Kanda Grant/research support from: Chugai Pharma Corporation, Pfizer, Abbvie, UCB, Bristol-Myers Squibb, Janssen Pharma, and Nichi-Iko Pharmaceutical Corporation., T. Kojima Speakers bureau: Takeda Pharma Corporation, Janssen Pharmaceutical, Astellas Pharma Corporation, Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Abbvie, Bristol-Myers Squibb, Pfizer, and Chugai Pharma Corporation., N. Ishiguro Speakers bureau: AbbVie, Chugai Pharma Corporation, Mitsubishi Tanabe Pharma Corporation, Daiichi-Sankyo, Eisai Pharma Corporation, Pfizer, and Takeda Pharma Corporation.